Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer
Annals of Oncology, 10/26/09

Jinno H et al. – These data indicate that the sequential combination of XT followed by FEC is a well-tolerated, effective neoadjuvant treatment of stage II/III breast cancer.

Methods

Patients with stage II/III breast cancer received 4 cycles of XT (capecitabine 1650 mg/m2 on days 1–14 and docetaxel 60 mg/m2 on day 8 every 3 weeks), followed by 4 cycles of FEC (5-fluorouracil 500 mg/m2, epirubicin 90 mg/m2, and cyclophosphamide 500 mg/m2 on day 1 every 3 weeks)
Primary end points were pathological complete response (pCR) rate and adverse drug reactions

Results

74 patients were enrolled and 71 patients assessable for clinical and pathological responses
Overall response rate was 91.5%
pCR rate 14.1% (10 of 71)
Grade 3/4 neutropenia observed in 32.4% of patients
Most common grade 3/4 non-hematologic adverse event was hand–foot syndrome, observed in 11.3% of patients
29 months median follow-up
2-year disease-free survival estimated 85% for all patients

<< Previous
Gender differences in professional development of healthcare...

Next >>
Maintenance pemetrexed plus best supportive care versus placebo...